Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.
The main objectives it aims to answer are:
To assess disease outcomes of PsA patients undergoing treatment for concomitant obesity and type 2 diabetes with GLP-1 analogs vs nutrition counseling.
To assess effectiveness as measured by clinical and patient reported outcome measures in patients treated with GLP-1 and nutrition counseling.
Participants will be randomized to receive a GLP-1 or nutrition counseling. Participants will be asked to come to the study center at most four times during a 24-week period. During this time participants will be asked to fill out questionnaires, receive a physical exam, and have their blood drawn.
Adult patients (age 18 and older) who present to rheumatology clinic
Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB).
Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA
Participants must have a Body Mass Index (BMI) of 30kg/m²
Any prior use of GLP-1 agonists
Inability to provide informed consent
Current participation in another PsA study
Treatment initiation by GLP-1 agonists contraindicated by FDA